Table 1.
Cancer genes and drug targets enrichment of GRNs
| Subtypes | Stage-specific GRNs | No. of genes | No. of links | No. of cancer genes (p-value) | No. of drug targets (p-value) |
|---|---|---|---|---|---|
| DCG_GRNs | Normal | 521 | 878 | 26 (0.0034) | 84 (0.039) |
| Adenoma | 766 | 1173 | 32 (0.0159) | 133 (0.0005) | |
| Carcinoma | 575 | 816 | 29 (0.0015) | 106 (0.0002) | |
| DEG_GRNs | Normal | 621 | 1087 | 28 (0.001) | 90 (0.307) |
| Adenoma | 706 | 1184 | 26 (0.12) | 119 (0.0098) | |
| Carcinoma | 604 | 955 | 25 (0.039) | 95 (0.058) | |
| WG_GRNs | Normal | 3344 | 4063 | 136 (0.43) | 456 (0.256) |
| Adenoma | 4072 | 5498 | 149 (0.489) | 558 (0.142) | |
| Carcinoma | 4099 | 5428 | 156 (0.92) | 573 (0.037) |
The enrichment significance (p-value) was calculated by Fisher’s Exact Test. Three types of GRNs, DCG-GRNs, DEG-GRNs and WG-GRNs, were included in this table. The latter two, DEG-GRNs and WG-GRNs, were described in the section of “Method comparison”.